83 related articles for article (PubMed ID: 17574050)
1. Beta2 microglobulin: a surprising therapeutic target for prostate cancer and renal cell carcinoma.
Freeman MR
J Urol; 2007 Jul; 178(1):10-1. PubMed ID: 17574050
[No Abstract] [Full Text] [Related]
2. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.
Nomura T; Huang WC; Seo S; Zhau HE; Mimata H; Chung LW
J Urol; 2007 Jul; 178(1):292-300. PubMed ID: 17499801
[TBL] [Abstract][Full Text] [Related]
3. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
4. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer.
Kawakami K; Hirata H; Yamamura S; Kikuno N; Saini S; Majid S; Tanaka Y; Kawamoto K; Enokida H; Nakagawa M; Dahiya R
Cancer Res; 2009 Nov; 69(22):8603-10. PubMed ID: 19887605
[TBL] [Abstract][Full Text] [Related]
5. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
6. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
[TBL] [Abstract][Full Text] [Related]
7. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.
Tang SW; Chang WH; Su YC; Chen YC; Lai YH; Wu PT; Hsu CI; Lin WC; Lai MK; Lin JY
Cancer Lett; 2009 Jan; 273(1):35-43. PubMed ID: 18809243
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy approach in prostate cancer cells using an active Wnt signal.
Giladi N; Dvory-Sobol H; Sagiv E; Kazanov D; Liberman E; Arber N
Biomed Pharmacother; 2007 Oct; 61(9):527-30. PubMed ID: 17904788
[TBL] [Abstract][Full Text] [Related]
10. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
[TBL] [Abstract][Full Text] [Related]
11. EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression.
Gu B; Ding Q; Xia G; Fang Z
Oncol Rep; 2009 Mar; 21(3):635-40. PubMed ID: 19212621
[TBL] [Abstract][Full Text] [Related]
12. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
[TBL] [Abstract][Full Text] [Related]
13. Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.
Konda R; Sugimura J; Sohma F; Katagiri T; Nakamura Y; Fujioka T
J Urol; 2008 Aug; 180(2):481-5. PubMed ID: 18550099
[TBL] [Abstract][Full Text] [Related]
14. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.
Sanlioglu AD; Karacay B; Koksal IT; Griffith TS; Sanlioglu S
Cancer Gene Ther; 2007 Dec; 14(12):976-84. PubMed ID: 17853923
[TBL] [Abstract][Full Text] [Related]
15. [Reabsorption of beta 2-microglobulin in the kidney during interferon-induced beta 2-microglobulin overproduction].
Kawamura J; Higashi Y; Yoshida O
Nihon Jinzo Gakkai Shi; 1985 Feb; 27(2):165-74. PubMed ID: 3894728
[No Abstract] [Full Text] [Related]
16. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Nicotera TM; Schuster DP; Bourhim M; Chadha K; Klaich G; Corral DA
Prostate; 2009 Sep; 69(12):1270-80. PubMed ID: 19475654
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; Sykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W
Clin Cancer Res; 2009 Jan; 15(2):650-9. PubMed ID: 19147771
[TBL] [Abstract][Full Text] [Related]
18. THE Wnt signalling pathway is a potential therapeutic target in prostate cancer.
Yardy GW; Brewster SF
BJU Int; 2006 Oct; 98(4):719-21. PubMed ID: 16978263
[No Abstract] [Full Text] [Related]
19. Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas.
Saini S; Liu J; Yamamura S; Majid S; Kawakami K; Hirata H; Dahiya R
Cancer Res; 2009 Sep; 69(17):6815-22. PubMed ID: 19723665
[TBL] [Abstract][Full Text] [Related]
20. Does prostate-specific antigen contribute to bone metastases?
Chirgwin JM; Guise TA
Clin Cancer Res; 2006 Mar; 12(5):1395-7. PubMed ID: 16533760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
